Amyloid toxicity and platelet-activating factor signaling

Journal of Cellular Physiology

Volumn 228, Issue 6, 2013, Pages 1143-1148

  Sirangelo, Ivana ^a   Irace, Gaetano ^a   Balestrieri, Maria Luisa ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; GINKGO BILOBA EXTRACT; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLIGOMER; REACTIVE OXYGEN METABOLITE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ACID BASE BALANCE; AMYLOIDOSIS; APOPTOSIS; ARTICLE; CALCIUM HOMEOSTASIS; CELL DEATH; CELL DISRUPTION; HUMAN; LONG TERM POTENTIATION; NERVE FIBER TRANSPORT; NERVOUS SYSTEM; NEUROPROTECTION; NEUROTOXICITY; OXIDATIVE STRESS; PRECURSOR; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; SIGNAL TRANSDUCTION;

AMYLOID; AMYLOIDOSIS; ANIMALS; HUMANS; INFLAMMATION MEDIATORS; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PLATELET ACTIVATING FACTOR; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

EID: 84874218692     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24284     Document Type: Article

References (121)

1. Aihara M, Ishii S, Kume K, Shimizu T. 2000. Interaction between neurone and microglia mediated by platelet-activating factor. Genes Neurons 5:397-406.
2. 2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 47:264-272.
3. Arai H. 2002. Platelet-activating factor acetylhydrolase. Prostaglandins Other Lipid Mediat 68-69:83-94.
4. Bae K, Longobardi L, Karasawa K, Malone B, Inoue T, Aoki J, Arai H, Inoue K, Lee T. 2000. Platelet-activating factor (PAF)-dependent transacetylase and its relationship with PAF acetylhydrolases. J Biol Chem 275:26704-26709.
5. Balestrieri ML, Servillo L, Lee T. 1997. The role of platelet-activating factor-dependent transacetylase in the biosynthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine by stimulated endothelial cells. J Biol Chem 272:17431-17437.
6. Balestrieri ML, Giovane A, Milone L, Servillo L. 2010. Endothelial progenitor cells express PAF receptor and respond to PAF via Ca(2+)-dependent signaling. Biochim Biophys Acta 1801:1123-1132.
7. Bate C, Salmona M, Williams A. 2004a. The role of platelet activating factor in prion and amyloid-beta neurotoxicity. Neuroreport 15:509-513.
8. Bate C, Salmona M, Williams A. 2004b. Ginkgolide B inhibits the neurotoxicity of prions or amyloid-beta 1-42. J Neuroinflam 1:4.
9. Bate C, Reid S, Williams A. 2004c. Phospholipase A2 inhibitors or platelet-activating factor antagonists prevent prion replication. J Biol Chem 279:36405-36411.
10. Bate C, Kempster S, Williams A. 2006. Platelet-activating factor antagonists protect amyloid-beta damaged neurons from microglia-mediated death. Neuropharmacology 51:173-181.
11. Bate C, Rumbold L, Williams A. 2007. Cholesterol synthesis inhibitors protect against platelet-activating factor-induced neuronal damage. J Neuroinflam 18:4-5.
12. Bate C, Tayebi M, Williams A. 2008. Ginkgolides protect against amyloid-beta 1-42-mediated synapse damage in vitro. Mol Neurodegener 3:1.
13. Bate C, Tayebi M, Williams A. 2010. Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration. Mol Neurodegener 8:5-13.
14. Bate C, Ingham V, Williams A. 2011. Inhibition of phospholipase A2 increased the removal of the prion derived peptide PrP82-146 from cultured neurons. Neuropharmacology 60:365-372.
15. Bazan NG. 2005. Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol 32:89-103.
16. Bazan NG, Tu B, Rodriguez de Turco EB. 2002. What synaptic lipid signaling tells us about seizure-induced damage and epileptogenesis. Prog Brain Res 135:175-185.
17. Bicca MA, Figueiredo CP, Piermartiri TC, Meotti FC, Bouzon ZL, Tasca CI, Medeiros R, Calixto JB. 2011. The selective and competitive N-methyl-D-aspartate receptor antagonist, (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid, prevents synaptic toxicity induced by amyloid-beta in mice. Neuroscience 192:631-641.
18. Birkle DL, Kurian P, Braquet P, Bazan NG. 1998. Platelet activating factor antagonist BN52021 decreases accumulation of free polyunsaturated fatty acid in mouse brain during ischemia and electroconvulsive shock. J Neurochem 51:1900-1905.
19. Bonin F, Ryan SD, Migahed L, Mo F, Lallier J, Franks DJ, Arai H, Bennett SA. 2004. Anti-apoptotic actions of the platelet activating factor acetylhydrolase I alpha 2 catalytic subunit. J Biol Chem 279:52425-52436.
20. Bordji K, Becerril-Ortega J, Nicole O, Buisson A. 2010. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-beta production. J Neurosci 30:15927-15942.
21. Brewer C, Bonin F, Bullock P, Nault MC, Morin J, Imbeault S, Shen TY, Franks DJ, Bennett SAL. 2002. Platelet activating factor-induced apoptosis is inhibited by ectopic expression of the platelet activating factor G-protein coupled receptor. J Neurochem 82:1502-1511.
22. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. 2002. Inherent toxicity of aggregates implies a common mechanism for protein misfolding disease. Nature 416:507-511.
23. Bucciantini M, Calloni G, Chiti F, Formigli L, Nosi D, Dobson CM, Stefani M. 2004. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem 279:31374-31382.
24. Butterfield AD, Drake J, Pocernich C, Castegna A. 2001. Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid b-peptide. Trends Mol Med 7:548-554.
25. Chen C, Magee JC, Marcheselli V, Hardy M, Bazan NG. 2001. Attenuated LTP in hippocampal dentate gyrus neurons of mice deficient in the PAF receptor. J Neurophysiol 85:384-390.
26. Chiti F, Dobson C. 2006. Protein misfolding, functional amyloid, and human diseases. Annu Rev Biochem 75:333-366.
27. Chiti F, Webster P, Taddei N, Clark A, Stefani M, Ramponi G, Dobson CM. 1999. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA 96:3590-3594.
28. Choi DW. 1992. Excitotoxic cell death. J Neurobiol 23:1261-1276.
29. Choi DW. 1994. Calcium and excitotoxic neuronal injury. Ann N Y Acad Sci 747:162-171.
30. Clark GD, Happel LT, Zorumski CF, Bazan NG. 1992. Enhancement of hippocampal excitatory synaptic transmission by platelet-activating factor. Neuron 9:1211-1216.
31. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL. 2007. Ab oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590-11601.
32. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. 2005. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280:17294-17300.
33. Demuro A, Parker I, Stutzmann GE. 2010. Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem 285:12463-12468.
34. Dobson CM. 2003. Protein folding and misfolding. Nature 426:884-890.
35. Evangelisti E, Wright D, Zampagni M, Cascella R, Bagnoli S, Relini A, Nichino D, Scartabelli T, Nacmias B, Sorbi S, Cecchi C. 2012. Lipid rafts mediate amyloid-induced calcium dyshomeostasis and oxidative stress in Alzheimer's disease. Curr Alzheimer Res PMID: 22950913.
36. Farooqui AA, Horrocks LA. 2006. Phospholipase A2-generated lipid mediators in the brain: The good, the bad, and the ugly. Neuroscientist 12:245-260.
37. Farooqui AA, Ong WY, Horrocks LA. 2006. Inhibitors of brain phospholipase A2 activity: Their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 58:591-620.
38. Farooqui AA, Ong WY, Farooqui T. 2010. Lipid mediators in the nucleus: Their potential contribution to Alzheimer's disease. Biochim Biophys Acta 1801:906-916.
39. Francescangeli E, Domanska-Janik K, Goracci G. 1996. Relative contribution of the de novo and remodelling pathways to the synthesis of platelet-activating factor in brain areas and during ischemia. J Lipid Mediat Cell Signal 14:89-98.
40. Gharibyan AL, Zamotin V, Yanamandra K, Moskaleva OS, Margulis BA, Kostanyan IA, Morozova-Roche LA. 2007. Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. J Mol Biol 365:1337-1349.
41. Goracci G, Balestrieri ML, Nardicchi V. 2009. Metabolism and functions of platelet activating factor (PAF) in the nervous tissue. Handbook of neurochemistry and molecular neurobiology. 3rd edition, Vol. 8. Springer US: Springer Science. 311-352 p.
42. Guijarro JI, Sunde M, Jones JA, Campbell ID, Dobson CM. 1998. Amyloid fibril formation by an SH3 domain. Proc Natl Acad Sci USA 95:4224-4228.
43. He Y, Cui J, Lee JC, Ding S, Chalimoniuk M, Simonyi A, Sun AY, Gu Z, Weisman GA, Wood WG, Sun GY. 2011. Prolonged exposure of cortical neurons to oligomeric amyloid-β impairs NMDA receptor function via NADPH oxidase-mediated ROS production: Protective effect of green tea (-)-epigallocatechin-3-gallate. ASN Neuro 3:e00050.
44. Hostettler ME, Knapp PE, Carlson SL. 2002. Platelet-activating factor induces cell death in cultured astrocytes and oligodendrocytes: Involvement of caspase-3. Glia 38:228-239.
45. Infusini G, Iannuzzi C, Vilasi S, Birolo L, Pagnozzi D, Pucci P, Irace G, Sirangelo I. 2012. Resolution of the effects induced by W→F substitutions on the conformation and dynamics of the amyloid-forming apomyoglobin mutant W7FW14F. Eur Biophys J 41:615-627.
46. Jang H, Zheng J, Lal R, Nussinov R. 2008. New structures help the modeling of toxic amyloid_ion channels. Trends Biochem Sci 33:91-100.
47. Jang H, Arce FT, Ramachandran S, Capone R, Lal R, Nussinov R. 2010a. Structural convergence among diverse, toxic beta-sheet ion channels. J Phys Chem 114:9445-9451.
48. Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL, Nussinov R, Lal R. 2010b. Truncated -amyloid peptide channels provide an alternative mechanism for Alzheimer's disease and Down syndrome. Proc Natl Acad Sci USA 107:6538-6543.
49. Jomova K, Vondrakova D, Lawson M, Valko M. 2010. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345:91-104.
50. Kadowaki H, Nishitoh H, Urano F, Sadamitsu C, Matsuzawa A, Takeda K, Masutani H, Yodoi J, Urano Y, Nagano T, Ichijo H. 2005. Amyloid β induces neuronal cell death through ROS mediated ASK1 activation. Cell Death Differ 12:19-24.
51. Kagan BL, Hirakura Y, Azimov R, Azimova R, Lin MC. 2002. The channel hypothesis of Alzheimer's disease: Current status. Peptides 23:1311-1315.
52. Kato K, Clark GD, Bazan NG, Zorumski CF. 1994. Platelet-activating factor as a potential retrograde messenger in CA1 hippocampal long-term potentiation. Nature 367:175-179.
53. Kawahara M, Kuroda Y, Arispe N, Rojas E. 2000. Alzheimer's b-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem 275:14077-14083.
54. Kayed R, Head E, Thomson JL, Mcintire TM, Milton SC, Cotman CW, Glabe CG. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489.
55. Kirkitadze MD, Bitan G, Teplow DB. 2002. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. J Neurosci Res 69:567-577.
56. Kowara R, Moraleja KL, Chakravarthy B. 2008. PLA(2) signaling is involved in calpain-mediated degradation of synaptic dihydropyrimidinase-like 3 protein in response to NMDA excitotoxicity. Neurosci Lett 430:197-202.
57. Kriem B, Sponne I, Fifre A, Malaplate-Armand C, Lozac'h-Pillot K, Koziel V, Yen-Potin FT, Bihain B, Oster T, Olivier JL, Pillot T. 2005. Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide. FASEB J 19:85-87.
58. Lehtonen JY, Holopainen JM, Kinnunen PK. 1996. Activation of phospholipase A2 by amyloid beta-peptides in vitro. Biochemistry 35:9407-9414.
59. Li T, Southall MD, Yi Q, Pei Y, Lewis D, Al-Hassani M, Spandau D, Travers JB. 2003. The epidermal platelet-activating factor receptor augments chemotherapy-induced apoptosis in human carcinoma cell lines. J Biol Chem 278:16614-16621.
60. Li J, Hu J, Shao B, Zhou W, Cui Y, Dong C, Ezoulin JM, Zhu X, Ding W, Heymans F, Chen H. 2009. Protection of PMS777, a new AChE inhibitor with PAF antagonism, against amyloid-beta-induced neuronal apoptosis and neuroinflammation. Cell Mol Neurobiol 29:589-595.
61. Litvinovich SV, Brew SA, Aota S, Akiyama SK, Haudenschild C, Ingham KC. 1998. Formation of amyloid like fibrils by self association of a partially unfolded fibronectin type III module. J Mol Biol 280:245-258.
62. Lu C, Chan SL, Haughey N, Lee WT, Mattson MP. 2001. Selective and biphasic effect of the membrane lipid peroxidation product 4-hydroxy-2, 3-nonenal on N-methyl-D-aspartate channels. J Neurochem 78:577-589.
63. Ma X, Bazan HE. 2001. Platelet-activating factor (PAF) enhances apoptosis induced by ultraviolet radiation in corneal epithelial cells through cytochrome c-caspase activation. Curr Eye Res 23:326-335.
64. 2-induced neuronal apoptosis. J Neurochem 73:1181-1188.
65. Malinow R. 2012. New developments on the role of NMDA receptors in Alzheimer's disease. Curr Opi Neurobiol 22:559-563.
66. Mark RJ, Hensley K, Butterfield DA, Mattson MP. 1995. Amyloid beta-peptide impairs ion-motive ATPase activities: Evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J Neurosci 15:6239-6249.
67. Mattson MP. 2004. Pathways towards and away from Alzheimer's disease. Nature 430:631-639.
68. Mattson MP. 2007. Calcium and neurodegeneration. Aging Cell 6:337-350.
69. Minghetti L. 2004. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63:901-910.
70. Nishizawa Y. 2001. Glutamate release and neuronal damage in ischemia. Life Sci 69:369-381.
71. Nogami K, Hirashima Y, Endo S, Takaku A. 1997. Involvement of platelet-activating factor (PAF) in glutamate neurotoxicity in rat neuronal cultures. Brain Res 754:72-78.
72. Novitskaya V, Bocharova OV, Bronstein I, Baskakov IV. 2006. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J Biol Chem 281:13828-13836.
73. Ortore MG, Spinozzi F, Vilasi S, Sirangelo I, Irace G, Shukla A, Narayanan T, Sinibaldi R, Mariani P. 2011. Time-resolved small-angle X-ray scattering study of the early stage of amyloid formation of an apomyoglobin mutant. Phys Rev E Stat Nonlin Soft Matter Phys 84:061904.
74. Padrick SB, Miranker AD. 2002. Islet amyloid: Phase partitioning and secondary nucleation are central to the mechanism of fibrillogenesis. Biochemistry 41:4694-4703.
75. Pedersen JS, Dikov D, Flink JL, Hjuler HA, Christiansen G, Otzen D. 2005. The changing face of glucagon fibrillation: Structural polymorphism and conformational imprinting J Mol Biol 355:501-523.
76. Pellistri F, Bucciantini M, Relini A, Gliozzi A, Robello M, Stefani M. 2008. Generic interaction of pre-fibrillar amyloid aggregates with NMDA and AMPA receptors results in free Ca2+ increase in primary neuronal cells. J Biol Chem 283:29950-29960.
77. Perry SW, Hamilton JA, Tjoelker LW, Dbaibo G, Dzenko KA, Epstein G, Hannun Y, Whittaker JS, Dewhurst S, Gelbard HA. 1998. Platelet activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. J Biol Chem 273:17660-17664.
78. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. 2000. Platelet activating factor and related lipid mediators. Annu Rev Biochem 69:419-445.
79. Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. 2004. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 101:2817-2822.
80. Ryan SD, Harris CS, Mo F, Lee H, Hou ST, Bazan NG, Haddad PS, Arnason JT, Bennett SA. 2007. Platelet activating factor-induced neuronal apoptosis is initiated independently of its G-protein coupled PAF receptor and is inhibited by the benzoate orsellinic acid. J Neurochem 103:88-97.
81. Ryan SD, Harris CS, Carswell CL, Baenziger JE, Bennett SA. 2008. Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. J Lipid Res 49:2250-2258.
82. Ryan SD, Whitehead SN, Swayne LA, Moffat TC, Hou W, Ethier M, Bourgeois AJ, Rashidian J, Blanchard AP, Fraser PE, Park DS, Figeys D, Bennett SA. 2009. Amyloid-beta42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism. Proc Natl Acad Sci USA 106:20936-20941.
83. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cissé M, Scearce-Levie K, Cheng IH, Gan L, Palop JJ, Bonventre JV, Mucke L. 2008. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11:1311-1318.
84. Sattayaprasert P, Choi HB, Ryu JK, Kim SU, Chongthammakun S, McLarnon JG. 2004. P19-1 Platelet-activating factor mediated inflammatory cytokine expression in human microglia. J Neurochem 88(s1):47.
85. Sattayaprasert P, Choi HB, Chongthammakun S, McLarnon JG. 2005. Platelet-activating factor enhancement of calcium influx and interleukin-6 expression, but not production, in human microglia. J Neuroinflam 2:11.
86. Sepulveda FJ, Parodi J, Peoples RW, Opazo C, Aguayo LG. 2010. Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS ONE 5:e11820.
87. Serpell LC, Sunde M, Benson MD, Tennent GA, Pepys MB, Fraser PE. 2000. The protofilament substructure of amyloid fibrils. J Mol Biol 300:1033-1039.
88. Serrano F, Chang A, Hernandez C, Pautler RG, Sweatt JD, Klann E. 2009. NADPH oxidase mediates b-amyloid peptide-induced activation of ERK in hippocampal organotypic cultures. Mol Brain 2:31.
89. Shelat PB, Chalimoniuk M, Wang JH, Strosznajder JB, Lee JC, Sun AY, Simonyi A, Sun GY. 2008. Amyloid b peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem 106:45-55.
90. Sherman MY, Goldberg AL. 2001. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron 29:15-32.
91. 2 and PAF mediate Abeta1-42-induced Ca2+ dyshomeostasis that is blocked by EGb761. Neurochem Int 56:893-905.
92. Shindou H, Hishikawa D, Nakanishi H, Harayama T, Ishii S, Taguchi R, Shimizu T. 2007. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:LYSO-PAF acetyltransferase. J Biol Chem 282:6532-6539.
93. Shukla SD. 1992. Platelet-activating factor receptor and signal transduction mechanisms. FASEB J 6:2296-2301.
94. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. 2010. Amyloid fibril protein nomenclature: 2010. Recommendations of the nomenclature committee of the International Society of Amyloidosis. Amyloid 17:101-104.
95. Sirangelo I, Irace G. 2010. Inhibition of aggregate formation as therapeutic target in protein misfolding diseases: Effect of tetracycline and trehalose. Expert Opin Ther Targets 14:1311-1321.
96. Sirangelo I, Iannuzzi C, Vilasi S, Irace G, Giuberti G, Misso G, D'Alessandro A, Abbruzzese A, Caraglia M. 2009. W7FW14F apomyoglobin amyloid aggregates-mediated apoptosis is due to oxidative stress and AKT inactivation caused by Ras and Rac. J Cell Physiol 221:412-423.
97. Snyder F. 1995. Platelet-activating factor: The biosynthetic and catabolic enzymes. Biochem J 305:689-705.
98. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Greengard GKGP. 2005. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8:1051-1058.
99. Sorrentino A, Giosafatto CV, Sirangelo I, De Simone C, Di Pierrop P, Porta R, Mariniello L. 2012. Higher susceptibility to amyloid fibril formation of the recombinant ovine prion protein modified by transglutaminase. Biochim Biophys Acta 1822:1509-1515.
100. Stefani M. 2004. Protein misfolding and aggregation: New examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta 1739:5-25.
101. Stefani M, Dobson CM. 2003. Protein aggregation and aggregate toxicity: New insights into protein foldinf, misfolding diseases and biological evolution. J Mol Med 81:679-699.
102. Stephenson DT, Lemere CA, Selkoe DJ, Clemens JA. 1996. Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol Dis 3:51-63.
103. Sun GY, Xu J, Jensen MD, Simonyi A. 2004. Phospholipase A2 in the central nervous system: Implications for neurodegenerative diseases. J Lipid Res 45:205-213.
104. Sun GY, Horrocks LA, Farooqui AA. 2007. The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegenerative diseases. J Neurochem 103:1-16.
105. Sunde M, Blake C. 1997. The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem 50:123-159.
106. Texido L, Martin-Satue M, Alberdi E, Solsona C, Matute C. 2011. Amyloid β peptide oligomers directly activate NMDA receptors. Cell Calcium 49:184-190.
107. Tong N, Sanchez JF, Maggirwar SB, Ramirez SH, Guo H, Dewhurst S, Gelbard HA. 2001. Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur J Neurosci 13:1913-1922.
108. Uemura Y, Lee TC, Snyder F. 1991. A coenzyme A-independent transacylase is linked to the formation of platelet-activating factor (PAF) by generating the lyso-PAF intermediate in the remodeling pathway. J Biol Chem 266:8268-8272.
109. Uversky VN. 2010. Mysterious oligomerization of the amyloidogenic proteins. FEBS J 277:2940-2953.
110. Verdier Y, Penke B. 2004. Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease. Curr Protein Pept Sci 5:19-31.
111. Verges DK, Restivo JL, Goebel WD, Holtzman DM, Cirrito JR. 2011. Opposing synaptic regulation of amyloid-beta metabolism by NMDA receptors in vivo. J Neurosci 31:11328-11337.
112. Vilasi S, Iannuzzi C, Portaccio M, Irace G, Sirangelo I. 2008. Effect of trehalose on W7FW14F apomyoglobin and insulin fibrillization: New insight into inhibition activity. Biochemistry 47:1789-1796.
113. Vilasi S, Sirangelo I, Irace G, Caputo I, Barone MV, Esposito C, Ragone R. 2010. Interaction of "toxic" and "immunogenic" A-gliadin peptides with a membrane-mimetic environment. J Mol Recognit 23:322-328.
114. Vilasi S, Sarcina R, Maritato R, De Simone A, Irace G, Sirangelo I. 2011. Heparin induces harmless fibril formation in amyloidogenic W7FW14F apomyoglobin and amyloid aggregation in wild-type protein in vitro. PLoS ONE 6:e22076.
115. Walsh DM, Selkoe DJ. 2007. A β oligomers-A decade of discovery. J Neurochem 101:1172-1184.
116. Wang W, Hou XY, Gao C, Liu Y, Zong YY, Zhang GY. 2003. Regulation of c-Jun N-terminal kinase activation in hydrogen peroxide induced neurotoxicity. J Neurocytol 32:143-151.
117. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. 2004. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24:3370-3378.
118. Wheal HV, Chen Y, Mitchell J, Schachner M, Maerz W, Wieland H, Van Rossum D, Kirsch J. 1998. Molecular mechanisms that underlie structural and functional changes at the postsynaptic membrane during synaptic plasticity. Prog Neurobiol 55:611-640.
119. Wieraszko A, Li G, Kornecki E, Hogan MV, Ehrlich YH. 1993. Longterm potentiation in the hippocampus induced by platelet-activating factor. Neuron 10:553-557.
120. Xu Y, Tao YX. 2004. Involvement of the NMDA receptor/nitric oxide signal pathway in platelet-activating factor-induced neurotoxicity. Neuroreport 15:263-266.
121. Yang X, Askarova S, Lee JC. 2010. Membrane biophysics and mechanics in Alzheimer's disease. Mol Neurobiol 41:138-148.